The Effect of a Local Injection of a Platelet Concentrate on Infection and Healing of Surgical Wounds

Overview

The purpose of this project is to investigate whether a combination of a local injection of platelet rich plasma (PRP) combined with a daily supplement of vitamin C, zinc, L-arginine, as well as high protein diet (1.5 g of protein per kilo body weight per day) can promote tissue healing in patients undergoing open upper-abdominal surgery. Primary endpoint is cases of wound infection and secondary endpoints are time of tissue regeneration (days), judged by traditional clinical observation and experimentally assessed by ultrasound. The experiment is performed as a parallel two-armed, randomized, controlled trial. A total of 40 subjects will be included in the trial i order to ensure the power of the study, despite a drop off of up to 25%.

Full Title of Study: “The Effect of L-PRP on Wound Healing and Wound Infection After Pancreaticoduodenectomy / Whipples Surgery”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2017

Interventions

  • Other: Leucocyte – Platelet rich Plasma
    • Autologous L-PRP are studied regarding it’s accelerating effect on tissue repair.
  • Dietary Supplement: Vitamin C
    • A daily dietary supplement of 500 mg Vitamin C. Provided from POD2-3 until POD30
  • Dietary Supplement: Zinc
    • A daily dietary supplement of 44 mg Zinc. Provided from POD2-3 until POD30
  • Dietary Supplement: L-Arginine
    • A daily dietary supplement of 5 g L-Arginine. Provided from POD2-3 until POD30

Arms, Groups and Cohorts

  • Experimental: Leucocyte – Platelet rich Plasma and Dietary Supplements
    • An application of an autologous platelet concentrate (20 ml). This is injected once, locally in the muscle after closure of the inner fascia and before closure of the outer fascia. A daily dietary supplement of Vitamin C, Zinc and L-Arginine. Provided from POD2-3 until POD30
  • No Intervention: Treatment as usual
    • Patients are treated as usual.

Clinical Trial Outcome Measures

Primary Measures

  • Number of patients with wound infection assessed by traditional clinical observation of the cicatrice
    • Time Frame: From date of surgery until the date of first documented event of infection or date of death from any cause, whichever came first, assessed up to 30 days .
    • Infection are defined as a collection of pus in the wound that require revision. It is assessed by observation from the hospital staff.

Secondary Measures

  • Number of days before the surgical wound are full epithelized assessed by observation of the cicatrice
    • Time Frame: Up to 30 days
    • Digital photos of the cicatrice will be collected and analyzed for the amount of remaining scab.
  • Other postoperative complications
    • Time Frame: Up to 30 days
  • Length of stay (LOS)
    • Time Frame: 30 days
  • Experience of pain assessed by a VAS (Visual analogue scale)
    • Time Frame: Up to 30 days
  • Mobilization assessed by “Timed Up & Go (TUG)”
    • Time Frame: Up to 30 days
    • Timed Up & Go, also known as TUG, measures the time it takes a study subject to stand up, walk 3 meters, turn around, walk back and sit down.
  • Inflammatory responds assessed by blood sample analysis of the acute phase reactant CRP (c-reactive protein)
    • Time Frame: Up to 30 days
  • Inflammatory responds assessed by blood sample analysis of the acute phase reactant leucucytes
    • Time Frame: Up to 30 days

Participating in This Clinical Trial

Inclusion Criteria

  • Patient at Rigshospitalets Surgical gastroenterology clinic – Planned to have a Pancreaticoduodenectomy preformed – Being able to understand Danish, the trial and what it means to be enrolled in the trial – Capable of signing a written consent – Living i the Regional Capital (excl. Bornholm) or the Regional of Sjælland (north of Næstved) Exclusion Criteria:
  • Dysregulated diabetes mellitus type I or II – Alcohol consumption above 14 or 7 x 12 g alcohol per week (men vs women) – Participating in another clinical trial
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • Jens Rikardt Andersen
    • Collaborator
      • Rigshospitalet, Denmark
    • Provider of Information About this Clinical Study
      • Sponsor-Investigator: Jens Rikardt Andersen, Associate Professor, MD – University of Copenhagen

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.